Abstract
New strategies in vaccine development are urgently needed to combat emerging influenza viruses and to reduce the risk of pandemic disease surfacing. Being conserved, the M2e protein, is a potential candidate for universal vaccine development against influenza A viruses. Mycobacterium tuberculosis Hsp70 (mHsp70) is known to cultivate the function of immunogenic antigenpresenting cells, stimulate a strong cytotoxic T lymphocyte (CTL) response, and stop the induction of tolerance. Thus, in this study, a recombinant protein from the extracellular domain of influenza A virus matrix protein 2 (M2e), was fused to the C-terminus of Mycobacterium tuberculosis Hsp70 (Hsp70c), to generate a vaccine candidate. Humoral immune responses, IFN-γ-producing lymphocyte, and strong CTL activity were all induced to confirm the immunogenicity of M2e.Hsp70c (Hsp70359–610). And challenge tests showed protection against H1N1 and H9N2 strains in vaccinated groups. Finally these results demonstrates M2e.Hsp70c fusion protein can be a candidate for a universal influenza A vaccine.
References
Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, Khan M I, Burkhard P. 2012. A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection. Influenza Res Treat, 2011:126794. doi: 10.1155/2011/126794. Epub 2012 Jan 12.
Bessa J, Schmitz N, Hinton H J, Schwarz K, Jegerlehner A, Bachmann M F. 2008. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol, 38: 114–126.
Bijker M S, van den Eeden S J, Franken K L, Melief C J, Offringa R, van der Burg S H. 2007. CD8+ CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol, 179: 5033–5040.
Black R A, Rota P A, Gorodkova N, Klenk H D, Kendal A P. 1993. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol, 74(Pt1): 143–146.
Bolhassani A, Rafati S. 2008. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines, 7: 1185–1199.
Carrat F, Vergu E, Ferguson N M, Lemaitre M, Cauchemez S, Leach S, Valleron A J. 2008. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol, 167: 775–785.
Chen C H, Wang T L, Hung C F, Yang Y, Young R A, Pardoll D M, Wu T C. 2000. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res, 60: 1035–1042.
Cox N J, Subbarao K. 2000. Global epidemiology of influenza: past and present. Annu Rev Med, 51: 407–421.
De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W. 2005. Universal influenza A vaccine: optimization of M2-based constructs. Virology, 337: 149–161.
De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londono-Arcila P, Fiers W, Saelens X. 2008. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine, 26: 6503–6507.
De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X. 2008. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem, 283: 11382–11387.
Ebrahimi S M, Tebianian M. 2010. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein. Mol Biol Rep, 37: 2877–2883.
Ebrahimi S M, Tebianian M. 2011. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes, 42: 1–8.
Ebrahimi S M, Dabaghian M, Tebianian M, Jazi M H. 2012. In contrast to conventional inactivated influenza vaccines, 4xM2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology, 430(1):63–72.
Ebrahimi S M, Tebianian M, Toghyani H, Memarnejadian A, Attaran H R. 2010. Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein Expr Purif, 70: 7–12.
Ernst W A, Kim H J, Tumpey T M, Jansen A D, Tai W, Cramer D V, Adler-Moore J P, Fujii G. 2006. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine, 24: 5158–5168.
Fan J, Liang X, Horton M S, Perry H C, Citron M P, Heidecker G J, Fu T M, Joyce J, Przysiecki C T, Keller P M, Garsky V M, Ionescu R, Rippeon Y, Shi L, Chastain M A, Condra J H, Davies M E, Liao J, Emini E A, Shiver J W. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine, 22: 2993–3003.
Fiers W, Neirynck S, Deroo T, Saelens X, Jou W M. 2001. Soluble recombinant influenza vaccines. Philos Trans R Soc Lond B Biol Sci, 356: 1961–1963.
Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. 2004. A "universal" human influenza A vaccine. Virus Res, 103: 173–176.
Frace A M, Klimov A I, Rowe T, Black R A, Katz J M. 1999. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine, 17: 2237–2244.
Fu T M, Grimm K M, Citron M P, Freed D C, Fan J, Keller P M, Shiver J W, Liang X, Joyce J G. 2009. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine, 27: 1440–1447.
Grandea A G, 3rd, Olsen O A, Cox T C, Renshaw M, Hammond P W, Chan-Hui P Y, Mitcham J L, Cieplak W, Stewart S M, Grantham M L, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A, 107: 12658–12663.
Haga T, Horimoto T. 2010. Animal Models to Study Influenza Virus Pathogenesis and Control The Open Antimicrobial Agents Journal, 2: 15–21.
Holsinger L J, Lamb R A. 1991. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology, 183: 32–43.
Huleatt J W, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans R K, Umlauf S, Tussey L, Powell T J. 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine, 26: 201–214.
Ionescu R M, Przysiecki C T, Liang X, Garsky V M, Fan J, Wang B, Troutman R, Rippeon Y, Flanagan E, Shiver J, Shi L. 2006. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J Pharm Sci, 95: 70–79.
Jazi M H, Dabaghian M, Tebianian M, Gharagozlou M J, Ebrahimi S M. 2012. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Virus Res, 167(2):219–25.
Kutzler M A, Weiner D B. 2008. DNA vaccines: ready for prime time? Nat Rev Genet, 9: 776–788.
Lamb R A, Zebedee S L, Richardson C D. 1985. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell, 40: 627–633.
Lau L L, Cowling B J, Fang V J, Chan K H, Lau E H, Lipsitch M, Cheng C K, Houck P M, Uyeki T M, Peiris J S, Leung G M. 2010. Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis, 201: 1509–1516.
Li X, Yang X, Li L, Liu H, Liu J. 2006. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine, 24: 3321–3331.
Liu W, Li H, Chen Y H. 2003. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol, 35: 141–146.
Liu W, Zou P, Ding J, Lu Y, Chen Y H. 2005. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect, 7: 171–177.
Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen Y H. 2004. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine, 23: 366–371.
Lu X, Tumpey T M, Morken T, Zaki S R, Cox N J, Katz J M. 1999. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol, 73: 5903–5911.
Macken C, Lu H, Goodman J, Boykin L. 2001. The value of a database in surveillance and vaccine selection. International Congress Series, 1219: 103–106.
Mirzaei N, Mokhtari Azad T, Nategh R, Soleimanjahi H, Amirmozafari N. 2014. Construction of recombinant bacmid containing m2e-ctxb and producing the fusion protein in insect cell lines. Iran Red Crescent Med J, 16(2):e13176. doi: 10.5812/ircmj.13176. Epub 2014 Feb 7.
Mozdzanowska K, Furchner M, Zharikova D, Feng J, Gerhard W. 2005. Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol, 79: 5943–5951.
Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Jr., Gerhard W. 2003. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine, 21: 2616–2626.
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou W M, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med, 5: 1157–1163.
Pinto L H, Holsinger L J, Lamb R A. 1992. Influenza virus M2 protein has ion channel activity. Cell, 69: 517–528.
Qazi K R, Wikman M, Vasconcelos N M, Berzins K, Stahl S, Fernandez C. 2005. Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene. Vaccine, 23: 1114–1125.
Reed L J, Muench H A. 1983. Simple method for estimating fifty per cent endpoints. Am. J. Epidemiol., 27: 493–497
Reid A H, Fanning T G, Janczewski T A, McCall S, Taubenberger J K. 2002. Characterization of the 1918 “Spanish” influenza virus matrix gene segment. J Virol, 76: 10717–10723.
Rimmelzwaan G F, Baars M, Claas E C, Osterhaus A D. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods, 74: 57–66.
Sealy R, Surman S, Hurwitz J L, Coleclough C. 2003. Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens. Immunology, 108: 431–439.
Segal B H, Wang X Y, Dennis C G, Youn R, Repasky E A, Manjili M H, Subjeck J R. 2006. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today, 11: 534–540.
Seo S H, Hoffmann E, Webster R G. 2002. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med, 8: 950–954.
Swinkels W J, Hoeboer J, Sikkema R, Vervelde L, Koets A D. 2013. Vaccination induced antibodies to recombinant avian influenza A virus M2 protein or synthetic M2e peptide do not bind to the M2 protein on the virus or virus infected cells. Virol J, 10:206.
Tompkins S M, Zhao Z S, Lo C Y, Misplon J A, Liu T, Ye Z, Hogan R J, Wu Z, Benton K A, Tumpey T M, Epstein S L. 2007. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis, 13: 426–435.
Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. 2008. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine, 26: 2100–2110.
WHO. 2002. Draft WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Wkly Epidemiol Rec, 77: 394–404.
Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan C C, Guo Y, Jiang S, Zheng B J, Zhou Y. 2010. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J, 7: 9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Attaran, H., Nili, H. & Tebianian, M. Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70359–610) fusion protein against influenza virus infection in mice. Virol. Sin. 29, 218–227 (2014). https://doi.org/10.1007/s12250-014-3428-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-014-3428-8
Keywords
- influenza A virus
- M2e.Hsp70
- recombinant fusion protein
- universal influenza vaccine